Cost-effective antimicrobial strategies

Antimicrobial Stewardship - Saving Bucks & Bugs

• Core Goal: Optimize clinical outcomes while minimizing unintended consequences like resistance, toxicity, and cost. Balances individual patient needs with public health.
• Key Interventions:
  • De-escalation: Narrowing antibiotic spectrum based on culture results. Go from broad to targeted.
  • IV-to-PO Switch: Convert to oral therapy once patient is stable, afebrile, and can tolerate PO intake. Reduces cost & complications.
  • Formulary Restriction: Limiting use of broad-spectrum or high-cost agents to specific criteria or requiring pre-authorization.
  • Dose Optimization: Using PK/PD principles for optimal killing and minimal toxicity.

⭐ Rapid Diagnostic Tests (e.g., MALDI-TOF, PCR) can decrease time to effective therapy by >24 hours, reducing length of stay and costs.

Core Strategies - The Switch & Ditch

Two key principles to reduce antimicrobial cost, resistance, and complications.

---

1. IV-to-PO Switch Therapy

• When? Patient must be:
  • Hemodynamically stable
  • Afebrile for >24 hours
  • Showing clinical improvement (↓ WBC, ↓ symptoms)
  • Able to tolerate oral intake (functioning GI tract)
• Why? ↓ Hospital stay, ↓ costs, ↓ risk of catheter-related infections.
• What? Use drugs with high oral bioavailability.

• When? As soon as culture & sensitivity (C&S) data are available.
• What? Switch from broad-spectrum empiric therapy to a narrow-spectrum agent.
• Why? ↓ Selective pressure for multidrug-resistant organisms & ↓ collateral damage.
• 📌 Mnemonic: Stop the "shotgun" approach; use a "sniper rifle" once the target is known.

⭐ Exam Favorite: Don't assume an oral version exists! IV-only drugs like carbapenems and piperacillin-tazobactam require switching to an entirely different agent (e.g., a fluoroquinolone or cephalosporin) based on sensitivities for the PO route.

Stewardship Metrics - The Numbers Game

• Primary Goal: Quantify antimicrobial use to guide interventions & assess impact.
• Key Consumption Metrics:
  • Defined Daily Doses (DDD): Assumed average maintenance dose per day for a drug.
    • Unit: DDDs per 100 patient-days.
    • Use: Benchmarking consumption across institutions.
    • Limitation: Doesn't reflect actual prescribed doses (e.g., renal adjustments).
  • Days of Therapy (DOT): Number of days a patient receives an antimicrobial, regardless of dose.
    • Unit: DOTs per 1,000 patient-days.
    • Use: More patient-centric; reflects true therapy duration.

⭐ DOT is preferred over DDD for internal hospital tracking as it accurately reflects antibiotic exposure, unlike DDD which can be skewed by dose adjustments (e.g., for renal failure).

• Outcome Metrics:
  • ↓ Hospital Length of Stay (LOS).
  • ↓ Antimicrobial cost.
  • ↓ C. difficile infection rates.

High‑Yield Points - ⚡ Biggest Takeaways

• De-escalation therapy is critical: start with broad-spectrum coverage, then narrow down based on culture and sensitivity results to reduce cost and resistance.
• Early IV-to-PO switch for clinically stable patients significantly cuts costs and shortens hospital stays.
• Utilize dose optimization strategies, like extended-infusion beta-lactams, to maximize efficacy and minimize waste.
• Formulary restrictions and pre-authorization are key tools for antimicrobial stewardship programs (ASPs).
• Always consider generic equivalents over brand-name drugs.